| 乳腺癌ER、PR、HER2表达与FEC新辅助化疗疗效的相关性研究 |
| |
| 引用本文： | 熊秋云,吴晓波,杜哲明. 乳腺癌ER、PR、HER2表达与FEC新辅助化疗疗效的相关性研究[J]. 重庆医学, 2011, 40(4). DOI: 10.3969/j.issn.1671-8348.2011.04.005 |
| |
| 作者姓名： | 熊秋云 吴晓波 杜哲明 |
| |
| 作者单位： | 熊秋云,吴晓波,Xiong Qiuyun,Wu Xiaobo(江西省南昌市第三医院,330009);杜哲明,Du Zheming(武警江西总队医院,南昌,330000) |
| |
| 摘 要： | 目的 探讨乳腺癌雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER2)表达与FEC(5-氟尿嘧啶、表柔比星、环磷酰胺)方案新辅助化疗疗效的相关性.方法 乳腺癌患者在接受FEC方案新辅助化疗前用免疫组织化学法检测乳腺癌组织中ER、PR和HER2的表达情况,新辅助化疗3周期结束后进行疗效评价,分析它们之间的相关性.结果 ER和PR阴性表达组47例,有效率(RR)为80.85%,其中病理完全缓解(pCR)率为23.40%.ER和(或)PR阳性表达组43例,RR为60.47%,其中pCR 率为6.98%.两组RR及pCR率比较,差异均有统计学意义(P＜0.05).HER2阳性表达组32例,RR为65.63%,其中pCR 率为12.50%.HER2阴性表达组58例,RR为74.14%,其中pCR 率为17.24%.两组RR及pCR率比较,差异均无统计学意义(P＞0.05).结论 ER、PR双阴性者可能较单阳性或双阳性者对FEC方案化疗的敏感性更高.
|
| 关 键 词： | 乳腺肿瘤 受体,雌激素 受体,表皮生长因子 新辅助化疗 |
Correlation of ER,PR,HER2 expressions and response to FEC neoadjuvant chemotherapy in breast cancer |
| |
| Xiong Qiuyun,Wu Xiaobo,Du Zheming. Correlation of ER,PR,HER2 expressions and response to FEC neoadjuvant chemotherapy in breast cancer[J]. Chongqing Medical Journal, 2011, 40(4). DOI: 10.3969/j.issn.1671-8348.2011.04.005 |
| |
| Authors: | Xiong Qiuyun Wu Xiaobo Du Zheming |
| |
| Affiliation: | Xiong Qiuyun1,Wu Xiaobo1,Du Zheming2(1.Third Hospital of Nanchang,Nanchang,Jiangxi 330009,China,2.Armed Police Jiangxi Unit Hospital,Jiangxi 330000,China) |
| |
| Abstract: | Objective To study the correlation of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor 2(HER2)expressions and response to FEC neoadjuvant chemotherapy in breast cancer.Methods The ER,PR and HER2 expression situation in the patients with breast cancer were examined by immunohistochemically before the operation were treated with FEC neoadjuvant chemotherapy.The effects were evaluated after 3 cycles and the correlation between them was analyzed.Results In 47 patients with ... |
| |
| Keywords: | breast neoplasms receptor estrogen epidermal growth factor neoadjuvant chemotherapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
